Surrozen, a biotechnology company, went public via a SPAC merger with Consonance-HFW Acquisition in a $212m deal. Investors in the PIPE include Consonance Capital Management and The Column Group. "This financing supports that mission with experienced life sciences investors and capital. We believe that modulation of the Wnt pathway, the body’s own mechanism for tissue repair, has the potential to provide clinical benefit in a broad range of acute and chronic diseases. In 2022, we expect to initiate Phase 1 clinical trials for our lead programs in inflammatory bowel disease and severe alcoholic hepatitis and to advance our ophthalmology programs towards IND. Today’s announcement ensures that we have the capital to advance our clinical programs to key clinical proof-of-concept milestones," Craig Parker, Surrozen President and CEO.